Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Slightly Bearish -15

Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher

AI-generated analysis

πŸ“‰ Novo Nordisk stock dropped 7% to $40.26 after guiding to peer-average revenue growth through 2030, signaling a slowdown in the high-growth expectations previously priced into the Ozempic and Wegovy maker.

⚠️ CEO Mike Doustdar confirmed the U.S. patent on semaglutide expires in 2032, threatening the product that currently accounts for over half of the company's annual sales revenue.

πŸ”„ The company is reversing its strategy to sharpen focus on obesity and diabetes, instead pivoting toward a diversified portfolio spanning blood disorders, liver disease, and cardiovascular conditions by 2030.

πŸ“Š Eli Lilly (LLY) stock slipped only 0.7% to $1,145.04, demonstrating that the market reaction was company-specific rather than a broad repricing of the entire GLP-1 obesity sector.

πŸ’° Viking Therapeutics (VKTX) edged higher by 1%, as capital rotated toward next-generation obesity challengers while investors fled the incumbent Novo Nordisk.

πŸ“ˆ The SPDR S&P 500 ETF Trust (SPY) gained 0.6% while the Health Care Select Sector SPDR (XLV) slipped slightly, isolating the decline to Novo Nordisk's specific strategic guidance.

Risk Factors
  • Eli Lilly stock slipped 0.7% as a direct competitor to Novo Nordisk, though the move was isolated and did not reflect a broad sector-wide repricing of obesity drug valuations.
  • The broader market context shows that while rivals like Viking Therapeutics are gaining attention as challengers, Eli Lilly remains largely unaffected by Novo Nordisk's specific patent cliff fears.
Full Analysis
Novo Nordisk's stock fell 7% following its capital markets day in London, where CEO Mike Doustdar guided the company to peer-average revenue growth through 2030. This guidance, which represents a slower expansion rate than historically expected for the Ozempic and Wegovy maker, triggered a multiple compression as investors repriced the stock from an outlier status to a standard industry performer. The selloff was driven primarily by concerns over the impending loss of key patent exclusivity on semaglutide in the U.S. in 2032, a product that currently drives more than half of Novo Nordisk's annual sales. CEO Doustdar acknowledged the 'patent cliff' and noted that while almost every pharmaceutical company is now competing in the weight-loss market, the company plans to emerge as a larger, more diversified business beyond obesity and diabetes. Unlike a broad sector repricing, rival GLP-1 competitor Eli Lilly saw its stock slip only 0.7%, indicating the negative sentiment was specific to Novo Nordisk's strategic pivot rather than a general downturn in the obesity drug market. The article notes that while Novo Nordisk is diversifying into blood disorders and cardiovascular disease, this strategy shift reverses previous focus sharpening, adding uncertainty to future growth projections. Analysts suggest investors should treat the explicitly stated patent cliff and peer-average growth framing as confirmed risks, potentially moderating position sizes in the near term. The market is currently working to determine how much of the discount reflects pre-existing concerns versus new information from the strategy day, with traders watching for stabilization once materials are fully digested.